Shire to Host Investor Call

Dublin (ots/PRNewswire) -

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART)
IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS

OF SUCH JURISDICTION.

Shire plc ("Shire" or the "Company") will today host a call for
investors at 1pm BST / 8am EDT, as announced on Friday June 20th.

A further press release will be issued today at midday BST / 7am
EDT with highlights related to the presentation at 1pm BST.

The details of the conference call are as follows:

UK dial in: 08082370030 or 02031394830
US dial in: 1 866 928 7517 or 1 718 873 9077
International
Access
Numbers: http://wpc.1726.planetstream.net/001726/FEL_Events_International_Access_List.pdf
Password/Conf
ID: 40849384#
Live Webcast: http://www.shire.com/shireplc/en/investors

Replay:

A replay of the presentation will be available for two weeks by
phone and by webcast for three months. Details can be found on our
Investor Relations website:
http://www.shire.com/shireplc/en/investors.

ACCESS TO CALL AND PRESENTATION

The investor call and the presentation are not directed at, or to
be accessed or attended by, persons located or resident in any
jurisdiction where the relevant action would constitute a violation
of the relevant laws and regulations of such jurisdiction or would
result in a requirement to comply with any governmental or other
consent or any registration, filing or other formality which Shire
regards as unduly onerous. All persons resident or located outside
the United Kingdom or the United States who wish to attend or access
the call or materials must first satisfy themselves that they are not
subject to any local requirements that prohibit or restrict them from
doing so and should inform themselves of, and observe, any applicable
legal or regulatory requirements applicable in their jurisdiction.
Shire and its advisers do not assume any responsibility for any
violation by any person of any of these restrictions.

The information provided during the call and in the presentation
is being made available in good faith and for information purposes
only and does not constitute an offer to sell or otherwise dispose of
or an invitation or solicitation of any offer to purchase or
subscribe for any securities or otherwise in any jurisdiction in
which such offer or solicitation is unlawful.

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better
lives.

Our strategy is to focus on developing and marketing innovative
specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases,
Gastrointestinal, and Internal Medicine and we are developing
treatments for symptomatic conditions treated by specialist
physicians in other targeted therapeutic areas, such as
Ophthalmology.

http://www.shire.com

For further information please contact:
Investor Relations
Jeff Poulton
jpoulton@shire.com
+1-781-482-0945

Sarah Elton-Farr
seltonfarr@shire.com
+44(0)1256-894157

Media
Jessica Mann
jmann@shire.com
+44(0)1256-894-280

Stephanie Fagan
sfagan@shire.com
+1-201-572-9581

ots Originaltext: Shire Pharmaceuticals Group Plc
Im Internet recherchierbar: http://www.presseportal.de